New York, NY (PRWEB) August 26, 2014
NewYork-Presbyterian/Columbia University Medical Center is finding new ways to use individualized, internal radiation delivered in the operating room immediately after a cancer tumor is removed. Intraoperative radiotherapy, or IORT, represents an effort to reduce the chance of a recurrence, shorten the duration of conventional postoperative external radiation, and reduce the risk to healthy tissue associated with external radiation.
In 2012, NewYork-Presbyterian Hospital became the first hospital in New York City to offer IORT to women with certain breast cancers. In this therapy, a spherical applicator is used to deliver a single, even dose of radiation to the inside surface of a rounded cavity after a lumpectomy.
Now, physicians at NewYork-Presbyterian/Columbia are expanding these pioneering efforts by offering IORT for other types of cancer in the abdomen and pelvis. Unlike that in the breast, the tumor bed in the abdomen and pelvis may not be as clearly defined after surgery, and several sites at risk for recurrence may need to be treated.
Earlier this year, in the hospital’s first case of using IORT for a cancer other than breast cancer, a woman with recurrent colon cancer in the pelvic cavity needed to have treatment to separate areas of her body. The surgeon, Ravi Kiran, MD, the Kenneth A. Forde Professor of Surgery (in Epidemiology) and chief of colorectal surgery at NewYork-Presbyterian/Columbia, removed the tumor, but could not cut too close to vital blood vessels and other organs. Because of the limitations of surgery, and because the patient had already received a high lifetime cumulative dose of radiation therapy in previous treatments, Dr. Kiran and Clifford Chao, MD, the Chu H. Chang Professor of Radiation Oncology and chair of radiation oncology at NewYork-Presbyterian/Columbia, decided to use IORT to “mop up” any leftover tumor cells. Dr. Chao used a flat radiotherapy applicator to deliver radiation to areas close to blood vessels along the pelvic wall and a spherical applicator to treat a region lower in the pelvic cavity. “We also used a protective wrap, or draping, made of material that shields organs like the bowel or blood vessels from scatter radiation,” Dr. Chao said.
In a second procedure, which involved a 23-year-old woman with a bile duct tumor, two differently shaped applicators were used to deliver IORT to the retroperitoneal tissue after removal of the tumor and nearby lymph nodes. The surgery, performed by Tomoaki Kato, MD, the Edwin C. and Anne K. Weiskopf Professor of Surgical Oncology and chief of abdominal organ transplantation at NewYork-Presbyterian/Columbia, was the first case nationally to use ZEISS INTRABEAM flat applicators after removal of a bile duct tumor. The flat applicator was used to deliver radiation to the surface where the retroperitoneal aortic lymph node had been. A sphere-shaped applicator was inserted into the right lobe of the liver near the hepatic artery, where the soft organ could completely surround the tiny globe and absorb a 20–30-minute, low-dose IORT treatment.
“Because of the way the tumor needs to be removed, or because the spaces between a tumor and large vessels and nerves are too small, microscopic lesions are more likely to be attached to the surface of blood vessels and nerves. IORT allows us to treat those areas and lower the risk of recurrence,” said Dr. Chao, who performed the radiation therapy procedure and is leading the hospital’s IORT efforts.
In a third case, Jason Wright, MD, the Levine Family Associate Professor of Women’s Health (in Obstetrics and Gynecology) and chief of gynecologic oncology at NewYork-Presbyterian/Columbia, used a similar approach to treat a gynecologic cancer, working with Dr. Chao.
In certain breast cancer cases, IORT has eliminated an additional 6–7 weeks of radiation therapy and, according to a 10-year randomized trial published in 2010, yielded the same results as conventional full-breast radiation. Dr. Chao is hopeful that similar benefits will be seen in other types of cancer cases, and he sees this as another step toward personalized cancer care.
“The possibilities are encouraging,” said Dr. Chao. “We could see patients ahead of time and then work with the surgeon to develop a personalized radiation treatment for the specific tumor.”
“When you open up the abdomen to remove a tumor from the liver, bowel, or pancreas, the terrain of the surgical bed is a more open, uneven surface,” he said. “So we need radiotherapy applicators that suit the specific anatomical terrain. In some areas of the body, the applicator could be a half sphere, an irregular shape for uneven surfaces, or a tiny device that fits into a small space where we have anatomic challenges. We can devise personalized therapy based on a patient’s specific anatomy.”
Dr. Chao is currently working with engineers and physicists from NewYork Presbyterian/Columbia and NewYork-Presbyterian/Weill Cornell Medical Center to design and develop applicators for colorectal, head and neck, lung, and gynecologic cancers.
ZEISS INTRABEAM is a mobile radiation oncology platform that offers additional treatment options for a wide range of cancer types, through use of its FDA-cleared spherical, needle, flat, and surface applicators. Because of the low X-ray energy, INTRABEAM does not require any complex radiation shielding measures and is suitable even for mobile use.
The physicians declare no financial or other conflicts of interests.
NewYork-Presbyterian Hospital, based in New York City, is one of the nation’s largest and most comprehensive hospitals and a leading provider of inpatient, ambulatory, and preventive care in all areas of medicine. With some 2,600 beds and more that 6,500 affiliated physicians and 20,000 employees, NewYork-Presbyterian had more than 2 million visits in 2013, including close to 15,000 infant deliveries and more than 310,000 emergency department visits. NewYork-Presbyterian comprises six campuses: NewYork-Presbyterian/Weill Cornell Medical Center, NewYork-Presbyterian/Columbia University Medical Center, NewYork-Presbyterian/Morgan Stanley Children's Hospital, NewYork-Presbyterian/The Allen Hospital, NewYork-Presbyterian/Westchester Division, and NewYork-Presbyterian/Lower Manhattan Hospital. The hospital is also closely affiliated with NewYork-Presbyterian/Lawrence Hospital in Bronxville. NewYork-Presbyterian is the #1 hospital in the New York metropolitan area, according to U.S. News & World Report, and consistently named to the magazine’s Honor Roll of best hospitals in the nation. Affiliated with two world-renowned medical schools, Weill Cornell Medical College and Columbia University College of Physicians and Surgeons, NewYork-Presbyterian is committed to excellence in patient care, research, education, and community service. For more information, visit http://www.nyp.org.
Columbia University Medical Center
Columbia University Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit cumc.columbia.edu or columbiadoctors.org.